(Q79805859)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Spinal muscular atrophy: advances in research and consensus on care of patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

main subject

spinal muscular atrophy

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Ching H Wang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 November 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

Current treatment options in neurology

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

420-428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11940-008-0044-7

26 December 2019

exact match

0 references

cites work

Riluzole attenuates spinal muscular atrophy disease progression in a mouse model.

1 reference

12 December 2020

Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy

1 reference

12 December 2020

Reliability of 4 outcome measures in pediatric spinal muscular atrophy.

1 reference

12 December 2020

Consensus Statement for Standard of Care in Spinal Muscular Atrophy

1 reference

12 December 2020

Directed differentiation of embryonic stem cells into motor neurons

1 reference

12 December 2020

Correction of disease-associated exon skipping by synthetic exon-specific activators

1 reference

12 December 2020

SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials

1 reference

12 December 2020

A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report

1 reference

12 December 2020

Chemical genetics and orphan genetic diseases.

1 reference

12 December 2020

A placebo-controlled trial of gabapentin in spinal muscular atrophy

1 reference

12 December 2020

SMN oligomerization defect correlates with spinal muscular atrophy severity

1 reference

12 December 2020

Spinal muscular atrophy: clinical classification and disease heterogeneity

1 reference

12 December 2020

Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts

1 reference

12 December 2020

In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate

1 reference

12 December 2020

In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy

1 reference

12 December 2020

134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11-13 February 2005, Naarden, The Netherlands.

1 reference

12 December 2020

The effect of hydroxyurea in spinal muscular atrophy cells and patients

1 reference

12 December 2020

Pilot trial of albuterol in spinal muscular atrophy

1 reference

12 December 2020

Readthrough of dystrophin stop codon mutations induced by aminoglycosides

1 reference

12 December 2020

Issues in SMA clinical trial design. The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design

1 reference

12 December 2020

Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts

1 reference

12 December 2020

Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury.

1 reference

12 December 2020

A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy

1 reference

12 December 2020

Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA

1 reference

12 December 2020

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy

1 reference

12 December 2020

Pilot trial of phenylbutyrate in spinal muscular atrophy

1 reference

12 December 2020

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy

1 reference

12 December 2020

Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism

1 reference

12 December 2020

Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients

1 reference

12 December 2020

Structure and organization of the human survival motor neurone (SMN) gene

1 reference

12 December 2020

Reliability of hand-held dynamometry in spinal muscular atrophy

1 reference

12 December 2020

Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals

1 reference

12 December 2020

What's up and down with histone deacetylation and transcription?

1 reference

12 December 2020

Treatment of spinal muscular atrophy by sodium butyrate

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy

1 reference

12 December 2020

Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon

1 reference

12 December 2020

Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy

1 reference

12 December 2020

Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients

1 reference

12 December 2020

Valproic acid increases SMN levels in spinal muscular atrophy patient cells.

1 reference

12 December 2020

An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN

1 reference

12 December 2020

A Phase 1 Trial of Riluzole in Spinal Muscular Atrophy

1 reference

12 December 2020

Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy.

1 reference

12 December 2020

Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway

1 reference

12 December 2020

A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

1 reference

12 December 2020

Identification and characterization of a spinal muscular atrophy-determining gene

1 reference

12 December 2020

Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells

1 reference

12 December 2020

Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2)

1 reference

12 December 2020

Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats

1 reference

12 December 2020

10.1007/S11940-008-0044-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18990310%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference